Daratumumab is safe and induces a rapid hematological response in light-chain amyloidosis with severe cardiac impairment.

Systemic light-chain (AL) amyloidosis is a plasma cell disorder characterized by extracellular deposition of monoclonal immunoglobulin light chains leading to organ dysfunction. Cardiac involvement...